Literature DB >> 28559263

Efficient Killing of Planktonic and Biofilm-Embedded Coagulase-Negative Staphylococci by Bactericidal Protein P128.

Nethravathi Poonacha1, Sandhya Nair1, Srividya Desai1, Darshan Tuppad1, Deepika Hiremath1, Thulasi Mohan1, Aradhana Vipra1, Umender Sharma2.   

Abstract

Coagulase-negative staphylococci (CoNS) are the major causative agents of foreign-body-related infections, including catheter-related bloodstream infections. Because of the involvement of biofilms, foreign-body-related infections are difficult to treat. P128, a chimeric recombinant phage-derived ectolysin, has been shown to possess bactericidal activity on strains of Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). We tested the killing potential of P128 on three clinically significant species of CoNS, S. epidermidis, S. haemolyticus, and S. lugdunensis, under a variety of physiological conditions representing growing and nongrowing states. The MIC90 and minimum bactericidal concentration at which 90% of strains tested are killed (MBC90) of P128 on 62 clinical strains of CoNS were found to be 16 and 32 μg/ml (0.58 and 1.16 μM), respectively, demonstrating the bactericidal nature of P128 on CoNS strains. Serum showed a potentiating effect on P128 inhibition, as indicated by 4- to 32-fold lower MIC values observed in serum. P128 caused a rapid loss of viability in all CoNS strains tested. Persisters of CoNS that were enriched in the presence of vancomycin or daptomycin were killed by P128 at 1× the MIC in a rapid manner. Low concentrations of P128 caused a 2- to 5-log reduction in CFU in stationary-phase or poorly metabolizing CoNS cultures. P128 at low concentrations eliminated CoNS biofilms in microtiter plates and on the surface of catheters. Combinations of P128 and standard-of-care (SoC) antibiotics were highly synergistic in inhibiting growth in preformed biofilms. Potent activity on planktonic cells, persisters, and biofilms of CoNS suggests that P128 is a promising candidate for the clinical development of treatments for foreign-body-related and other CoNS infections.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CRBSI; CoNS; P128; biofilms; catheter-related infections; coagulase-negative staphylococci; foreign-body-related infections; persisters; stationary phase; synergy

Mesh:

Substances:

Year:  2017        PMID: 28559263      PMCID: PMC5527639          DOI: 10.1128/AAC.00457-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  46 in total

Review 1.  Bacterial biofilms: a common cause of persistent infections.

Authors:  J W Costerton; P S Stewart; E P Greenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

Review 2.  Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics.

Authors:  Lorena Rodríguez-Rubio; Beatriz Martínez; David M Donovan; Ana Rodríguez; Pilar García
Journal:  Crit Rev Microbiol       Date:  2012-09-20       Impact factor: 7.624

3.  In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.

Authors:  Kristi L Frank; Emily J Reichert; Kerryl E Piper; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

Review 4.  Antimicrobial bacteriophage-derived proteins and therapeutic applications.

Authors:  Dwayne R Roach; David M Donovan
Journal:  Bacteriophage       Date:  2015-06-23

5.  The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri.

Authors:  Evgeny A Idelevich; Frieder Schaumburg; Dennis Knaack; Anna S Scherzinger; Wolfgang Mutter; Georg Peters; Andreas Peschel; Karsten Becker
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

6.  A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent antistaphylococcal protein.

Authors:  Vivek Daniel Paul; Sanjeev Saravanan Rajagopalan; Sudarson Sundarrajan; Shilpa E George; Jiya Y Asrani; Renjith Pillai; Ravisha Chikkamadaiah; Murali Durgaiah; Bharathi Sriram; Sriram Padmanabhan
Journal:  BMC Microbiol       Date:  2011-10-11       Impact factor: 3.605

7.  Catheter-related bloodstream infections.

Authors:  Rupam Gahlot; Chaitanya Nigam; Vikas Kumar; Ghanshyam Yadav; Shampa Anupurba
Journal:  Int J Crit Illn Inj Sci       Date:  2014-04

8.  Antibiotic regimen based on population analysis of residing persister cells eradicates Staphylococcus epidermidis biofilms.

Authors:  Shoufeng Yang; Iain D Hay; David R Cameron; Mary Speir; Bintao Cui; Feifei Su; Anton Y Peleg; Trevor Lithgow; Margaret A Deighton; Yue Qu
Journal:  Sci Rep       Date:  2015-12-21       Impact factor: 4.379

Review 9.  The emerging problem of linezolid-resistant Staphylococcus.

Authors:  Bing Gu; Theodoros Kelesidis; Sotirios Tsiodras; Janet Hindler; Romney M Humphries
Journal:  J Antimicrob Chemother       Date:  2012-09-04       Impact factor: 5.758

10.  Effective removal of staphylococcal biofilms by the endolysin LysH5.

Authors:  Diana Gutiérrez; Patricia Ruas-Madiedo; Beatriz Martínez; Ana Rodríguez; Pilar García
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

View more
  11 in total

Review 1.  Bacteriophages and Lysins in Biofilm Control.

Authors:  Marzanna Łusiak-Szelachowska; Beata Weber-Dąbrowska; Andrzej Górski
Journal:  Virol Sin       Date:  2020-03-03       Impact factor: 4.327

2.  Antibacterial Effects of Phage Lysin LysGH15 on Planktonic Cells and Biofilms of Diverse Staphylococci.

Authors:  Yufeng Zhang; Mengjun Cheng; Hao Zhang; Jiaxin Dai; Zhimin Guo; Xinwei Li; Yalu Ji; Ruopeng Cai; Hengyu Xi; Xinwu Wang; Yibing Xue; Changjiang Sun; Xin Feng; Liancheng Lei; Wenyu Han; Jingmin Gu
Journal:  Appl Environ Microbiol       Date:  2018-07-17       Impact factor: 4.792

Review 3.  Ways to control harmful biofilms: prevention, inhibition, and eradication.

Authors:  Wen Yin; Siyang Xu; Yiting Wang; Yuling Zhang; Shan-Ho Chou; Michael Y Galperin; Jin He
Journal:  Crit Rev Microbiol       Date:  2020-12-28       Impact factor: 7.624

Review 4.  Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy.

Authors:  Hugo Oliveira; Carlos São-José; Joana Azeredo
Journal:  Viruses       Date:  2018-05-29       Impact factor: 5.048

Review 5.  Bacteriophage - A Promising Alternative Measure for Bacterial Biofilm Control.

Authors:  Fengjuan Tian; Jing Li; Amina Nazir; Yigang Tong
Journal:  Infect Drug Resist       Date:  2021-01-20       Impact factor: 4.003

Review 6.  How Good are Bacteriophages as an Alternative Therapy to Mitigate Biofilms of Nosocomial Infections.

Authors:  Aditi Singh; Sudhakar Padmesh; Manish Dwivedi; Irena Kostova
Journal:  Infect Drug Resist       Date:  2022-02-17       Impact factor: 4.003

7.  Activity of the Chimeric Lysin ClyR against Common Gram-Positive Oral Microbes and Its Anticaries Efficacy in Rat Models.

Authors:  Jingjing Xu; Hang Yang; Yongli Bi; Wuyou Li; Hongping Wei; Yuhong Li
Journal:  Viruses       Date:  2018-07-20       Impact factor: 5.048

Review 8.  Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials.

Authors:  Roberto Vázquez; Ernesto García; Pedro García
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

9.  Recombinant of the Staphylococcal Bacteriophage Lysin CHAPk and Its Elimination against Streptococcus agalactiae Biofilms.

Authors:  Yuxue Shan; Na Yang; Da Teng; Xiumin Wang; Ruoyu Mao; Ya Hao; Xuanxuan Ma; Huan Fan; Jianhua Wang
Journal:  Microorganisms       Date:  2020-02-06

Review 10.  Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application.

Authors:  Katarzyna M Danis-Wlodarczyk; Daniel J Wozniak; Stephen T Abedon
Journal:  Antibiotics (Basel)       Date:  2021-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.